Achilles Therapeutics plc ACHL
1.48 0.00 (+0.00%)
At closeMar 20, 2025, 4:00 PM EDT
1.48 Day range 1.48
52-week range unavailable
- YTD
- +29.82%
- 1 year
- +14.73%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
globenewswire.com Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction -
globenewswire.com Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC…
globenewswire.com Achilles Therapeutics Reports Third Quarter 2024 Financial Results – Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –
zacks.com Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year? Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
globenewswire.com Achilles Therapeutics Announces Strategic Update –Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice– LONDON, Sept. 19,…
globenewswire.com Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates – Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles' AI-powered, tumor-targeting technology –
globenewswire.com Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines Research collaboration combines Achilles' best-in-class AI-driven, tumor-targeting technology with Arcturus' world-leading self-amplifying mRNA platform
globenewswire.com Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company's operations are not affected by the receipt of the Notice Achilles ADSs will continue to trade…
globenewswire.com Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights – Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H…
globenewswire.com Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights – Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated…
globenewswire.com Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three…
globenewswire.com Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal…
globenewswire.com Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies Newly developed computational tools and large…
globenewswire.com Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights – On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1…
globenewswire.com Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company's operations are not affected by the receipt of the Notice - - Achilles ADSs will continue to…
zacks.com Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year? Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and HealthEquity (HQY) have performed compared to their sector so far this year.
globenewswire.com Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights - Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma -
globenewswire.com Achilles Therapeutics to Present at Upcoming Conferences LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors,…
investorplace.com 3 Stocks With 1,000% Upside Potential If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside…
zacks.com Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year? Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared to their sector so far this year.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 241 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's trading, 138 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday saw 219 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 167 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 283 companies set new 52-week lows.
benzinga.com Why Qudian Shares Jumped Over 40%; Here Are 73 Biggest Movers From Yesterday Gainers AMTD Digital Inc. (NYSE: HKD) climbed 71.5% to close at $27.80 on Monday after gaining 108% on Friday. The company priced its IPO at $7 per share.- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 466 companies hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 368 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 209 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday morning saw 454 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 445 companies made new 52-week lows.- benzinga.com 48 Biggest Movers From Friday Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares climbed 58% to close at $5.45 on Friday.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the morning session on Thursday, 152 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Before 10 a.m. ET on Friday, 18 companies set new 52-week lows.
benzinga.com 51 Biggest Movers From Yesterday Gainers UTime Limited (NASDAQ: UTME) shares jumped 875% to close at $39.00 on Tuesday after the company priced its IPO at $4 per share.